Jinling Pharmaceutical Company Limited

Equities

000919

CNE0000010W5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
6.96 CNY +1.90% Intraday chart for Jinling Pharmaceutical Company Limited +8.75% -11.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jinling Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jinling Pharmaceutical Company Limited announced that it has received CNY 749.999998 million in funding from a group of investors CI
Jinling Pharma in Talks to Buy Over 50% Stake in Local Hospital MT
Jinling Pharmaceutical Company Limited agreed to acquire 43.6% stake in Nanjing Meishan Hospital Co., Ltd. from Nanjing New Industrial Investment Group Co.,Ltd. and Nanjing Zijin Investment Management Co., Ltd. CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jinling Pharma Selling 750 Million Yuan Shares to Fund New Projects MT
Jinling Pharmaceutical Company Limited Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 14 July 2023 CI
Jinling Pharmaceutical Company Limited Approves Management Appointments CI
Jinling Pharmaceutical Company Limited Approves Cash Dividend for the Year 2022 CI
Jinling Pharmaceutical Vice Chairman Resigns MT
Jinling Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jinling Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2022 CI
Jinling Pharmaceutical Company Limited announced that it expects to receive CNY 750 million in funding from Nanjing New Industrial Investment Group Co., Ltd and other investors CI
Jinling Pharma Gets 155 Million Yuan Compensation for Office Demolition, Relocation MT
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Jinling Pharmaceutical Company Limited Implements Final Profit Distribution for 2021, Payable on August 11, 2022 CI
Jinling Pharmaceutical Company Limited Approves Cash Dividend for the Year 2021 CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Jinling Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2021 CI
Chizhou Dongsheng Pharmaceutical Co., Ltd announced that it has received CNY 45 million in funding from Jinling Pharmaceutical Company Limited, Nanjing Core Tech Co., Ltd. CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chizhou Dongsheng Pharmaceutical Co., Ltd announced that it expects to receive CNY 45 million in funding from Jinling Pharmaceutical Company Limited, Nanjing Core Tech Co., Ltd. CI
Chart Jinling Pharmaceutical Company Limited
More charts
Jinling Pharmaceutical Company Limited is a China-based company principally engaged in the manufacture and sale of traditional Chinese medicines and chemical drugs. The Company’s main products include Mailuoning injections, ferrous succinate tablets and Lentinan injection, among others. The Company is also involved in the provision of medical services and the sale of medical instrument. The Company distributes its products in domestic market, with North China as its main market.
More about the company
  1. Stock Market
  2. Equities
  3. 000919 Stock
  4. News Jinling Pharmaceutical Company Limited
  5. Jinling Pharma in Talks to Buy Over 50% Stake in Local Hospital